panitumumab,bevacizumab
roche,takeda,amgen
['beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'crcsm', 'paradigm', 'panitumumab']
medscape: a suspicion from retrospective data has just been confirmed by the paradigm trial at #asco22: adding panitumumab to standard chemo in left-sided ras wild-type mcrc is more effective than adding bevacizumab. #crcsm 
Make life a little bit more cheerful is my main goal. I love to laugh, make people happy, and share interesting articles about health.